[en] Atopic dermatitis (AD) is one of the most common, bothersome and difficult to treat skin disorders. Recent introduction of new systemic treatments has revolutionized the management of AD. The goal of this guideline is to provide evidence-based recommendations for the management of patients suffering from atopic dermatitis that easily can be implemented in clinical practice. These recommendations were developed by 11 Belgian AD experts. Comments of all experts on the proposed statements were gathered, followed by an online voting session. The most relevant strategies for the management and treatment of AD in the context of the Belgian health care landscape are discussed. General measures, patient education and adequate topical treatment remain the cornerstones of AD management. For moderate to severe AD, the introduction of biologics and JAK inhibitors show unprecedented efficacy, although currently access is limited to a subgroup of patients meeting the reimbursement criteria.
Disciplines :
Dermatology
Author, co-author :
Lapeere, Hilde; Department of Dermatology, Ghent University Hospital, Ghent, Belgium
Speeckaert, Reinhart; Department of Dermatology, Ghent University Hospital, Ghent, Belgium
Baeck, Marie; Department of Dermatology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
Dezfoulian, Bita ; Centre Hospitalier Universitaire de Liège - CHU > > Service de dermatologie
Lambert, Julien; Department of Dermatology, University Hospital Antwerp (UZA), Edegem, Belgium
Roquet-Gravy, Pierre-Paul; Department of Dermatology, Grand Hôpital de Charleroi, Charleroi, Belgium
Stockman, Annelies; Department of Dermatology, AZ Delta campus Rembert Torhout, Torhout, Belgium
White, Jonathan; Department of Dermatology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
Castelijns, Francisca; Department of Dermatology, University Hospitals Leuven, Leuven, Belgium
Gutermuth, Jan; Vrije Universiteit Brussel (VUB), Department of Dermatology, Universitair Ziekenhuis Brussel, Brussels, Belgium
RBSDV - Royal Belgian Society of Dermatology and Venereology
Funding text :
for the project was provided to the Royal Belgian Society of Dermatology and Venerology by six pharmaceutical companies: Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis and UCB. These companies were, however, not involved in the making of the manuscript.
ChelloC, CarnicelliG, SernicolaA, et al. Atopic dermatitis in the elderly caucasian population: diagnostic clinical criteria and review of the literature. Int J Dermatol. 2020;59(6):716–721. doi: 10.1111/ijd.14891
HanifinJM, RajkaG.Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980;60:44–47. doi: 10.2340/00015555924447
WollenbergA, BarbarotS, BieberT, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: 10.1111/jdv.14891
WollenbergA, BarbarotS, BieberT, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850–878. doi: 10.1111/jdv.14888
DizonMP, YuAM, SinghRK, et al. Systematic review of atopic dermatitis disease definition in studies using routinely collected health data. Br J Dermatol. 2018;178(6):1280–1287. doi: 10.1111/bjd.16340
EichenfieldLF, TomWL, ChamlinSL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–351. doi: 10.1016/j.jaad.2013.10.010
LeshemYA, ChalmersJR, ApfelbacherC, et al. Measuring atopic eczema symptoms in clinical practice: the first consensus statement from the harmonising outcome measures for eczema in clinical practice initiative. J Am Acad Dermatol. 2020;82(5):1181–1186. doi: 10.1016/j.jaad.2019.12.055
HanifinJM, ThurstonM, OmotoM, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10(1):11–18. doi: 10.1034/j.1600-0625.2001.100102.x
YosipovitchG, ReaneyM, MasteyV, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761–769. doi: 10.1111/bjd.17744
Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European task force on atopic dermatitis. Dermatology. 1993;186(1):23–31. doi: 10.1159/000247298
CharmanCR, VennAJ, WilliamsHC.The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004;140(12):1513–1519. doi: 10.1001/archderm.140.12.1513
FinlayAY, KhanGK. Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x
PariserDM, SimpsonEL, GadkariA, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the atopic dermatitis control tool (ADCT). Curr Med Res Opin. 2020;36(3):367–376. doi: 10.1080/03007995.2019.1699516
BergmannMM, CaubetJ-C, BoguniewiczM, et al. Evaluation of food allergy in patients with atopic dermatitis. J Allergy Clin Immunol Pract. 2013;1(1):22–28. doi: 10.1016/j.jaip.2012.11.005
SampsonHA. The evaluation and management of food allergy in atopic dermatitis. Clin Dermatol. 2003;21(3):183–192. doi: 10.1016/S0738-081X(02)00363-2
SampsonHA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol. 2001;107(5):891–896. doi: 10.1067/mai.2001.114708
Lemon-MuléH, Nowak-WegrzynA, BerinC, et al. Pathophysiology of food-induced anaphylaxis. Curr Allergy Asthma Rep. 2008;8(3):201–208. doi: 10.1007/s11882-008-0034-6
BreuerK, WulfA, ConstienA, et al. Birch pollen-related food as a provocation factor of allergic symptoms in children with atopic eczema/dermatitis syndrome. Allergy. 2004;59(9):988–994. doi: 10.1111/j.1398-9995.2004.00493.x
DickelH, KuhlmannL, BauerA, et al. Atopy patch testing with aeroallergens in a large clinical population of dermatitis patients in Germany and Switzerland, 2000-2015: a retrospective multicentre study. J Eur Acad Dermatol Venereol. 2020;34(9):2086–2095. doi: 10.1111/jdv.16250
HamannCR, HamannD, EgebergA, et al. Association between atopic dermatitis and contact sensitization: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):70–78. doi: 10.1016/j.jaad.2017.02.001
ChenJK, JacobSE, NedorostST, et al. A pragmatic approach to patch testing atopic dermatitis patients: clinical recommendations based on expert Consensus opinion. Dermatitis. 2016;27(4):186–192. doi: 10.1097/DER.0000000000000208
van ZuurenEJ, FedorowiczZ, ChristensenR, et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;2:CD012119.
BoraleviF, Saint AromanM, DelarueA, et al. Long-term emollient therapy improves xerosis in children with atopic dermatitis. J Eur Acad Dermatol Venereol. 2014;28(11):1456–1462. doi: 10.1111/jdv.12314
SimpsonEL, ChalmersJR, HanifinJM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818–823. doi: 10.1016/j.jaci.2014.08.005
HorimukaiK, MoritaK, NaritaM, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):824–830.e6. doi: 10.1016/j.jaci.2014.07.060
MandeauA, AriesM-F, BoéJ-F, et al. Rhealba® oat plantlet extract: evidence of protein-free content and assessment of regulatory activity on immune inflammatory mediators. Planta Med. 2011;77(9):900–906. doi: 10.1055/s-0030-1250649
GuenicheA, KnaudtB, SchuckE, et al. Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol. 2008;159(6):1357–1363. doi: 10.1111/j.1365-2133.2008.08836.x
BianchiP, TheunisJ, CasasC, et al. Effects of a new emollient-based treatment on skin microflora balance and barrier function in children with mild atopic dermatitis. Pediatr Dermatol. 2016;33(2):165–171. doi: 10.1111/pde.12786
HalkenS, MuraroA, de SilvaD, et al. EAACI guideline: preventing the development of food allergy in infants and young children (2020 update). Pediatr Allergy Immunol. 2021;32(5):843–858. doi: 10.1111/pai.13496
Du ToitG, RobertsG, SayrePH, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015;372(9):803–813. doi: 10.1056/NEJMoa1414850
QueilleC, PommaredeR, SauratJH. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol. 1984;1(3):246–253. doi: 10.1111/j.1525-1470.1984.tb01124.x
CharmanC, WilliamsH. The use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clin Dermatol. 2003;21(3):193–200. doi: 10.1016/S0738-081X(02)00368-1
WollenbergA, OranjeA, DeleuranM, et al. ETFAD/EADV eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol. 2016;30(5):729–747. doi: 10.1111/jdv.13599
Aubert-WastiauxH, MoretL, Le RhunA, et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol. 2011;165(4):808–814. doi: 10.1111/j.1365-2133.2011.10449.x
LeeJY, HerY, KimCW, et al. Topical corticosteroid phobia among parents of children with atopic eczema in Korea. Ann Dermatol. 2015;27(5):499–506. doi: 10.5021/ad.2015.27.5.499
MüllerSM, TomaschettD, EulerS, et al. Topical corticosteroid concerns in dermatological outpatients: a cross-sectional and interventional study. Dermatology. 2016;232(4):444–452. doi: 10.1159/000446068
WollenbergA, Christen-ZächS, TaiebA, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744. doi: 10.1111/jdv.16892
PaghdalKV, SchwartzRA. Topical tar: back to the future. J Am Acad Dermatol. 2009;61(2):294–302. doi: 10.1016/j.jaad.2008.11.024
DiffeyBL, FarrPM, OakleyAM. Quantitative studies on UVA-induced erythema in human skin. Br J Dermatol. 1987;117(1):57–66. doi: 10.1111/j.1365-2133.1987.tb04091.x
GilchrestBA, SoterNA, HawkJL, et al. Histologic changes associated with ultraviolet A–induced erythema in normal human skin. J Am Acad Dermatol. 1983;9(2):213–219. doi: 10.1016/S0190-9622(83)70131-3
WilliamsHC, GrindlayDJC. What’s new in atopic eczema? An analysis of the clinical significance of systematic reviews on atopic eczema published in 2006 and 2007. Clin Exp Dermatol. 2008;33(6):685–688. doi: 10.1111/j.1365-2230.2008.02906.x
GambichlerT, OthlinghausN, TomiNS, et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br J Dermatol. 2009;160(3):652–658. doi: 10.1111/j.1365-2133.2008.08984.x
KwatraSG, MiseryL, ClibbornC, et al. Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics. Clin Transl Immunology. 2022;11(5):e1390. doi: 10.1002/cti2.1390
SherLG, ChangJ, PatelIB, et al. Relieving the pruritus of atopic dermatitis: a meta-analysis. Acta Derm Venereol. 2012;92(5):455–461. doi: 10.2340/00015555-1360
WollenbergA, EhmannLM. Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol. 2012;24(3):253–260. doi: 10.5021/ad.2012.24.3.253
WilliamsMR, GalloRL. The role of the skin microbiome in atopic dermatitis. Curr Allergy Asthma Rep. 2015;15(11):65. doi: 10.1007/s11882-015-0567-4
KongHH, SegreJA. Skin microbiome: looking back to move forward. J Invest Dermatol. 2012;132(3):933–939. doi: 10.1038/jid.2011.417
Bath-HextallFJ, BirnieAJ, RavenscroftJC, et al. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol. 2010;163(1):12–26. doi: 10.1111/j.1365-2133.2010.09743.x
DarsowU, WollenbergA, SimonD, et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol. 2010;24(3):317–328. doi: 10.1111/j.1468-3083.2009.03415.x
WongS, NgTG, BabaR. Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. J Dermatol. 2013;40(11):874–880. doi: 10.1111/1346-8138.12265
RyanC, ShawRE, CockerellCJ, et al. Novel sodium hypochlorite cleanser shows clinical response and excellent acceptability in the treatment of atopic dermatitis. Pediatr Dermatol. 2013;30(3):308–315. doi: 10.1111/pde.12150
SawadaY, TongY, BarangiM, et al. Dilute bleach baths used for treatment of atopic dermatitis are not antimicrobial in vitro. J Allergy Clin Immunol. 2019;143(5):1946–1948. doi: 10.1016/j.jaci.2019.01.009
ChiuLS, ChowVCY, LingJML, et al. Staphylococcus aureus carriage in the anterior nares of close contacts of patients with atopic dermatitis. Arch Dermatol. 2010;146(7):748–752. doi: 10.1001/archdermatol.2010.129
GaugerA, MempelM, SchekatzA, et al. Silver-coated textiles reduce Staphylococcus aureus colonization in patients with atopic eczema. Dermatology. 2003;207(1):15–21. doi: 10.1159/000070935
LopesC, SilvaD, DelgadoL, et al. Functional textiles for atopic dermatitis: a systematic review and meta-analysis. Pediatr Allergy Immunol. 2013;24(6):603–613. doi: 10.1111/pai.12111
VlachouC, ThomasKS, WilliamsHC. A case report and critical appraisal of the literature on the use of DermaSilk in children with atopic dermatitis. Clin Exp Dermatol. 2009;34:e901–903. doi: 10.1111/j.1365-2230.2009.03672.x
JaegerT, RothmaierM, ZanderH, et al. Acid-coated textiles (pH 5.5–6.5)–a new therapeutic strategy for atopic eczema?Acta Derm Venereol. 2015;95(6):659–663. doi: 10.2340/00015555-1916
LopesC, SoaresJ, TavariaF, et al. Chitosan coated textiles May improve atopic dermatitis severity by modulating skin staphylococcal profile: a randomized controlled trial. PLoS One. 2015;10(11):e0142844. doi: 10.1371/journal.pone.0142844
ThomasKS, BradshawLE, SachTH, et al. Silk garments plus standard care compared with standard care for treating eczema in children: a randomised, controlled, observer-blind, pragmatic trial (CLOTHES trial). PLOS Med. 2017;14(4):e1002280. doi: 10.1371/journal.pmed.1002280
WollenbergA, ZochC, WetzelS, et al. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J Am Acad Dermatol. 2003;49(2):198–205. doi: 10.1067/S0190-9622(03)00896-X
OngPY, LeungDYM. Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clin Rev Allergy Immunol. 2016;51(3):329–337. doi: 10.1007/s12016-016-8548-5
SchneiderL, WeinbergA, BoguniewiczM, et al. Immune response to varicella vaccine in children with atopic dermatitis compared with nonatopic controls. J Allergy Clin Immunol. 2010;126(6):1306–1307.e2. doi: 10.1016/j.jaci.2010.08.010
PesericoA, StädtlerG, SebastianM, et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol. 2008;158(4):801–807. doi: 10.1111/j.1365-2133.2008.08436.x
WerfelT, HeratizadehA, AbererW, et al. Update “systemic treatment of atopic dermatitis” of the S2k-guideline on atopic dermatitis. J Dtsch Dermatol Ges. 2021;19(1):151–168. doi: 10.1111/ddg.14371
BeckLA, ThaçiD, HamiltonJD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139. doi: 10.1056/NEJMoa1314768
ThaçiD, SimpsonEL, BeckLA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52. doi: 10.1016/S0140-6736(15)00388-8
SimpsonEL, BieberT, Guttman-YasskyE, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi: 10.1056/NEJMoa1610020
GutermuthJ, DelbekeH, KrepsE, et al. Beleid van oculaire manifestaties bij atopische dermatitis en dupilumab-geassocieerde conjunctivitis. Skin. 2021;24:31–35.
BieberT. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1):21–40. doi: 10.1038/s41573-021-00266-6
SchwartzDM, KannoY, VillarinoA, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17(1):78. doi: 10.1038/nrd.2017.267
SimpsonEL, LacourJ-P, SpelmanL, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–255. doi: 10.1111/bjd.18898
SiegfriedEC, JaworskiJC, KaiserJD, et al. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16(1):75. doi: 10.1186/s12887-016-0607-9
HanifinJ, GuptaAK, RajagopalanR. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol. 2002;147(3):528–537. doi: 10.1046/j.1365-2133.2002.05006.x
Berth-JonesJ, DamstraRJ, GolschS, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ. 2003;326(7403):1367. doi: 10.1136/bmj.326.7403.1367
Der Meer JBV, GlazenburgEJ, MulderPG, et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands adult atopic DermatitisStudy group. British Journal Of Dermatology. 1999;140(6):1115–1121. doi: 10.1046/j.1365-2133.1999.02893.x
